It seems Gilead Sciences 's stock trades with a discount. Many analysts say Gilead Sciences is currently undervalued. Currently the company is being followed by 10 researchers. The recommendations spread over: no sells, 5 times hold and no buys. The average target price (fair value) equals 87,5 USD. This is at around 23 percent more than the current price of 71,29 USD. Leerink Swann & Company, Berenberg and Jefferies & Co. recently provided recommendations for the stock.
Gilead Sciences 's market capitalization is based on the number of outstanding shares around 93,18 billion USD.
On Wednesday the stock closed at 71,29 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.